Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.56 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14791028 | 0.98 | HRH3 (0.69) | HRH3SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL14787825 | 0.98 | HRH3 (0.69) | HRH3SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL24061141 | 0.94 | HRH3 (0.82) | HRH3SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL20901800 | 0.93 | HRH3 (0.65) | HRH3SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL15467001 | 0.89 | HRH3 (0.87) | HRH3SMN1; SMN2LMNAALDH1A1MEN1 | |
| SCHEMBL14787893 | 0.88 | ALDH1A1 (0.59) | HRH3SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL11356824 | 0.85 | LMNA (0.83) | HRH3SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL7989530 | 0.85 | LMNA (0.83) | HRH3SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL1045922 | 0.85 | LMNA (0.83) | HRH3SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL7989269 | 0.85 | LMNA (0.83) | HRH3SMN1; SMN2LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102702137-A | Synthesis of chiral ionic liquid based on (R)-thiazolidine-2-thione-4-carboxylic acid | UNIV XIN JIANG | 2012-10-03 | — | — | CN | claimed |
| CN-120117949-A | Method for directly preparing tertiary amine compound from aromatic aldehyde, ketone and secondary amine | 湖南大学 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024072822-A2 | DISPERSING AND WETTING AGENTS AND COMPOSITIONS AND METHODS OF USE THEREOF | MOJAVE BIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-0453218-B1 | Conductive polyoxymethylene resin composition | ASAHI CHEMICAL IND (JP) | 1995-09-20 | — | — | EP | disclosed |
| US-5207949-A | Polyester | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1993-05-04 | — | — | US | disclosed |
| EP-0453218-A1 | Conductive polyoxymethylene resin composition | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | HRH3 2788/4885SMN1; SMN2 2827/4885LMNA 3513/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | HRH3 1501/4885SMN1; SMN2 4550/4885LMNA 4411/4885 |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PIK3CD, PIK3CA, PIK3R5 | HRH3 4098/4885SMN1; SMN2 3720/4885LMNA 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.